258 related articles for article (PubMed ID: 28112370)
21. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells.
Barsoum IB; Smallwood CA; Siemens DR; Graham CH
Cancer Res; 2014 Feb; 74(3):665-74. PubMed ID: 24336068
[TBL] [Abstract][Full Text] [Related]
22. Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells.
Sasidharan Nair V; Toor SM; Ali BR; Elkord E
Expert Opin Ther Targets; 2018 Jun; 22(6):547-557. PubMed ID: 29702007
[TBL] [Abstract][Full Text] [Related]
23. Type II cGMP‑dependent protein kinase inhibits EGF‑induced JAK/STAT signaling in gastric cancer cells.
Wu M; Wu Y; Lan T; Jiang L; Qian H; Chen Y
Mol Med Rep; 2016 Aug; 14(2):1849-56. PubMed ID: 27357186
[TBL] [Abstract][Full Text] [Related]
24. NADPH oxidase promotes pancreatic cancer cell survival via inhibiting JAK2 dephosphorylation by tyrosine phosphatases.
Lee JK; Edderkaoui M; Truong P; Ohno I; Jang KT; Berti A; Pandol SJ; Gukovskaya AS
Gastroenterology; 2007 Nov; 133(5):1637-48. PubMed ID: 17983808
[TBL] [Abstract][Full Text] [Related]
25. Bladder cancer cells induce immunosuppression of T cells by supporting PD-L1 expression in tumour macrophages partially through interleukin 10.
Wang X; Ni S; Chen Q; Ma L; Jiao Z; Wang C; Jia G
Cell Biol Int; 2017 Feb; 41(2):177-186. PubMed ID: 27987237
[TBL] [Abstract][Full Text] [Related]
26. Cucurmosin induces apoptosis of BxPC-3 human pancreatic cancer cells via inactivation of the EGFR signaling pathway.
Zhang B; Huang H; Xie J; Xu C; Chen M; Wang C; Yang A; Yin Q
Oncol Rep; 2012 Mar; 27(3):891-7. PubMed ID: 22139427
[TBL] [Abstract][Full Text] [Related]
27. Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia.
Wang X; Li J; Dong K; Lin F; Long M; Ouyang Y; Wei J; Chen X; Weng Y; He T; Zhang H
Cell Signal; 2015 Mar; 27(3):443-52. PubMed ID: 25499621
[TBL] [Abstract][Full Text] [Related]
28. Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; a potential mechanism for immune escape.
Elnemr A; Ohta T; Yachie A; Kayahara M; Kitagawa H; Ninomiya I; Fushida S; Fujimura T; Nishimura G; Shimizu K; Miwa K
Int J Oncol; 2001 Jan; 18(1):33-9. PubMed ID: 11115536
[TBL] [Abstract][Full Text] [Related]
29. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.
Barrett MT; Anderson KS; Lenkiewicz E; Andreozzi M; Cunliffe HE; Klassen CL; Dueck AC; McCullough AE; Reddy SK; Ramanathan RK; Northfelt DW; Pockaj BA
Oncotarget; 2015 Sep; 6(28):26483-93. PubMed ID: 26317899
[TBL] [Abstract][Full Text] [Related]
30. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma.
Du Z; Abedalthagafi M; Aizer AA; McHenry AR; Sun HH; Bray MA; Viramontes O; Machaidze R; Brastianos PK; Reardon DA; Dunn IF; Freeman GJ; Ligon KL; Carpenter AE; Alexander BM; Agar NY; Rodig SJ; Bradshaw EM; Santagata S
Oncotarget; 2015 Mar; 6(7):4704-16. PubMed ID: 25609200
[TBL] [Abstract][Full Text] [Related]
31. Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis.
Black M; Barsoum IB; Truesdell P; Cotechini T; Macdonald-Goodfellow SK; Petroff M; Siemens DR; Koti M; Craig AW; Graham CH
Oncotarget; 2016 Mar; 7(9):10557-67. PubMed ID: 26859684
[TBL] [Abstract][Full Text] [Related]
32. Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells.
Tong WG; Ding XZ; Hennig R; Witt RC; Standop J; Pour PM; Adrian TE
Clin Cancer Res; 2002 Oct; 8(10):3232-42. PubMed ID: 12374694
[TBL] [Abstract][Full Text] [Related]
33. PKC 412 small-molecule tyrosine kinase inhibitor: single-compound therapy for pancreatic cancer.
El Fitori J; Su Y; Büchler P; Ludwig R; Giese NA; Büchler MW; Quentmeier H; Hines OJ; Herr I; Friess H
Cancer; 2007 Oct; 110(7):1457-68. PubMed ID: 17676584
[TBL] [Abstract][Full Text] [Related]
34. Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer.
Noma B; Sasaki T; Fujimoto Y; Serikawa M; Kobayashi K; Inoue M; Itsuki H; Kamigaki M; Minami T; Chayama K
Int J Oncol; 2008 Dec; 33(6):1187-94. PubMed ID: 19020751
[TBL] [Abstract][Full Text] [Related]
35. Pancreatic Tumor Progression Associated With CD133 Overexpression: Involvement of Increased TERT Expression and Epidermal Growth Factor Receptor-Dependent Akt Activation.
Weng CC; Kuo KK; Su HT; Hsiao PJ; Chen YW; Wu DC; Hung WC; Cheng KH
Pancreas; 2016 Mar; 45(3):443-57. PubMed ID: 26646272
[TBL] [Abstract][Full Text] [Related]
36. Emodin potentiates the antiproliferative effect of interferon α/β by activation of JAK/STAT pathway signaling through inhibition of the 26S proteasome.
He Y; Huang J; Wang P; Shen X; Li S; Yang L; Liu W; Suksamrarn A; Zhang G; Wang F
Oncotarget; 2016 Jan; 7(4):4664-79. PubMed ID: 26683360
[TBL] [Abstract][Full Text] [Related]
37. Microcystin LR Shows Cytotoxic Activity Against Pancreatic Cancer Cells Expressing the Membrane OATP1B1 and OATP1B3 Transporters.
Kounnis V; Chondrogiannis G; Mantzaris MD; Tzakos AG; Fokas D; Papanikolaou NA; Galani V; Sainis I; Briasoulis E
Anticancer Res; 2015 Nov; 35(11):5857-65. PubMed ID: 26504008
[TBL] [Abstract][Full Text] [Related]
38. A sesquiterpene lactone antrocin from Antrodia camphorata negatively modulates JAK2/STAT3 signaling via microRNA let-7c and induces apoptosis in lung cancer cells.
Yeh CT; Huang WC; Rao YK; Ye M; Lee WH; Wang LS; Tzeng DT; Wu CH; Shieh YS; Huang CY; Chen YJ; Hsiao M; Wu AT; Yang Z; Tzeng YM
Carcinogenesis; 2013 Dec; 34(12):2918-28. PubMed ID: 23880305
[TBL] [Abstract][Full Text] [Related]
39. Synthetic small peptides acting on B7H1 enhance apoptosis in pancreatic cancer cells.
Wang F; Ma J; Liu J; Jin H; Huang D
Mol Med Rep; 2012 Sep; 6(3):553-7. PubMed ID: 22752249
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor induces STAT1 expression to exacerbate the IFNr-mediated PD-L1 axis in epidermal growth factor receptor-positive cancers.
Cheng CC; Lin HC; Tsai KJ; Chiang YW; Lim KH; Chen CG; Su YW; Peng CL; Ho AS; Huang L; Chang YC; Lin HC; Chang J; Chang YF
Mol Carcinog; 2018 Nov; 57(11):1588-1598. PubMed ID: 30035369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
